Artificial oocyte activation may improve embryo quality in older patients with diminished ovarian reserve undergoing IVF-ICSI cycles

Tzung-En Tsai¹, Pei-Hsuan Lin¹, Pei-Fen Lian¹, Chia-Jung Li¹,², Salvatore Giovanni Vitale³, Mislav Mikuš⁴, Wan-Ping Su¹, Hsiao-Wen Tsai¹, Kuan-Hao Tsui¹,²,⁵ and Li-Te Lin¹,²,⁵,⁶*

Abstract

Background: Artificial oocyte activation (AOA) is used to improve fertilization rate following fertilization failure after intracytoplasmic sperm injection (ICSI). Several studies have also shown that AOA may be involved in embryo development. Women with poor ovarian response are more likely to encounter in vitro fertilization (IVF) failure due to poor embryo quality. The aim of this study was to investigate whether AOA could improve embryo quality in older patients with diminished ovarian reserve undergoing IVF-ICSI cycles.

Methods: The retrospective cohort study consisted of 308 patients who fulfilled the POSEIDON Group 4 criteria and received IVF-ICSI cycles. The study group included 91 patients receiving AOA with calcium ionophores following ICSI. A total of 168 patients in the control group underwent ICSI without AOA. The baseline and cycle characteristics and embryo quality were compared between the two groups.

Results: At baseline, there were more IVF attempts, greater primary infertility, higher basal FSH levels and lower anti-Müllerian hormone (AMH) levels in the AOA group than in the non-AOA group. In terms of embryo quality, there were higher cleavage rates and top-quality Day 3 embryo (TQE) rates, as well as higher percentages of more than 1 TQE and TQE rates ≥50 in the AOA group than in the non-AOA group. The multivariate analysis revealed that AOA was positively associated with more than 1 TQE (adjusted OR 3.24, 95% CI 1.63–6.45, \( P = 0.001 \)) and a TQE rate ≥50 (adjusted OR 2.14, 95% CI 1.20–3.80, \( P = 0.010 \)). When the study population was divided into 2 subgroups based on the age of 40 years old, the beneficial effects of AOA on embryo quality were only observed in the subgroup of age ≥40 years old.

Conclusions: Our data suggest that AOA with calcium ionophores may improve embryo quality in older patients with diminished ovarian reserve undergoing IVF-ICSI cycles, especially in women aged ≥40 years.

Keywords: Artificial oocyte activation, Calcium ionophore, In vitro fertilization, Intracytoplasmic sperm injection, Embryo development, Embryo quality

Introduction

Intracytoplasmic sperm injection (ICSI) is a procedure involving the injection of one spermatozoon into the cytoplasm of an oocyte to improve fertilization and pregnancy in couples with male factor infertility.
The fertilization rate may reach 70% by ICSI. However, complete fertilization failure or an extremely low fertilization rate occurs in approximately 1~5% of ICSI cycles [2]. Fertilization failure is considered to be related to a deficiency of oocyte activation, which may be related to sperm or oocyte factors [3]. There are a series of complex molecular events related to oocyte activation that originate from the entry of sperm and result in oscillations from intracellular calcium released from the endoplasmic reticulum [4–6].

Artificial oocyte activation (AOA) is a way to artificially induce calcium release following ICSI and can be performed in a variety of ways, such as through chemical, mechanical or physical stimuli [7]. Calcium ionophores such as ionomycin and calcimycin are chemical agents most commonly used to induce oocyte activation [2, 3]. These chemical agents enhance intracellular calcium release from endoplasmic reticulum and facilitate the influx of extracellular calcium [8]. AOA is mainly used in patients with fertilization failure or a lower fertilization rate after ICSI, and several studies have demonstrated that AOA indeed improves the fertilization rate in these patients [9–11]. In addition, other studies have shown that increases in calcium signaling are an essential factor to induce both nuclear and cytoplasmic changes in fertilized oocytes and lead to not only oocyte activation but also early onset of embryogenesis [7, 8]. Furthermore, there are studies that suggest that AOA might improve embryo development [6, 12, 13].

Poor ovarian responders (PORs) are a group of women who have a poor response to ovarian stimulation during IVF cycles. Treating PORs is a great challenge due to their poor IVF outcomes [14]. As previously described, the definition of PORs varies widely in previous studies [14]. In 2016, the Patient-Oriented Strategies Encompassing Individualized Oocyte Number (POSEIDON) group proposed a new classification for patients with low prognosis to advocate an individualized approach [15]. POSEIDON Group 4 refers to women with advanced age and diminished ovarian reserve who usually have poor embryo quality and impaired IVF outcomes [16, 17]. The numbers of POSEIDON Group 4 patients are increasing and are more than half of the total population of the POSEIDON group [18, 19].

Taken together, we hypothesized that AOA could enhance embryo quality in PORs. Few studies have been published to explore this issue. Thus, a retrospective cohort study was designed to investigate the effects of AOA on embryo quality in patients who fulfilled POSEIDON Group 4 criteria and received IVF-ICSI treatment.

Materials and methods

Study design and participants
The retrospective cohort study was performed at the reproductive medical center of Kaohsiung Veterans General Hospital from January 2018 to September 2020. The study project was approved by the institutional review board at Kaohsiung Veterans General Hospital (reference number of institutional review board: KSVGH21-CT1–27). The requirement for consent was waived by the institutional review board because of its retrospective design. All patient data were collected from electronic medical records and IVF treatment sheets. Patients who received the first IVF-ICSI cycle in our reproductive medical center and fulfilled the criteria of POSEIDON Group 4 [age ≥35 years old, with antral follicle counts (AFCs)<5 and/or anti-Müllerian hormone (AMH)<1.2 ng/ml] were included in this study. A total of 308 patients met the POSEIDON Group 4 criteria. The exclusion criteria were as follows: (1) patients whose age was over 46 years old, (2) patients who were oocytes recipients, and (3) patients who obtained no metaphase II oocytes. Eventually, 259 POSEIDON Group 4 patients undergoing IVF-ICSI cycles were identified and divided into the AOA group (n=91) and the non-AOA group (n=168). A calcium ionophore was used to activate oocytes following the ICSI procedure in the AOA group but not in the non-AOA group. The study flow chart is shown in Fig. 1.

Treatment protocols
The stimulation protocols in the current study included the GnRH antagonist protocol, ultralong protocol, and progestin priming ovulation stimulation (PPOS) protocol. For the GnRH antagonist protocol, within 5 days of the menstrual cycle, controlled ovarian stimulation was initiated with a gonadotropin, such as recombinant follicle-stimulating hormone (rFSH) plus recombinant luteinizing hormone (Pergoveris, Merck Serono SA, Aubonne, Switzerland) or human menopausal gonadotropin (Merional, IBSA Institut Biochimique S.A., Lamone, Switzerland) after transvaginal ultrasound evaluation. GnRH antagonists (Cetrotide 0.25 mg, Pierre Fabre Medica- ment Production, Aquitaine Pharm International, Idron, France) were injected daily when the leading follicle reached a diameter of 12–14 mm. Once the leading follicle reached a diameter of 18 mm, final oocyte maturation was triggered by a dual trigger comprising recombinant human chorionic gonadotropin (rhCG, Ovidrel 250 μg, Merck Serono S.p.A., Modugno, Italy) and GnRH agonist (Lupro 2 mg, Nang Kuang Pharmaceutical Co, Ltd., Tainan, Taiwan). Oocyte retrieval with the guidance of transvaginal ultrasound was performed 36 hours later. For the ultralong protocol, a long-acting GnRH agonist...
(Leuplin Depot 3.75 mg S. C, Takeda Pharmaceutical Company Limited, Yodogawa-ku, Osaka, Japan) was pre-treated in the previous menstrual cycle. Controlled ovarian stimulation with gonadotropins as described above started approximately 4 weeks later. When the leading follicle reached a diameter of 18 mm, rhCG was used for oocyte triggering. Then, ultrasound-guided oocyte aspiration was conducted 36 hours later. In patients receiving the PPOS protocol, after evaluation of transvaginal ultrasound, controlled ovarian stimulation was started within 5 days of the menstrual cycle. Gonadotropins such as rFSH plus recombinant luteinizing hormone (Pergoveris, Merck Serono SA, Aubonne, Switzerland) or human menopausal gonadotropin (Merional, IBSA Institut Biochimique S.A., Lamone, Switzerland or Menopur, Ferring International Center SA, Saint-Prex, Switzerland) combined with oral medicines including 100 mg clomiphene citrate (Clomiphene tablets 50 mg, Yung Shin Pharmaceutical Industrial Co. LTD., Taichung, Taiwan) once per day and 10 mg medroxyprogesterone acetate (Provera 5 mg, Pfizer Italia S.r.l, Ascoli Piceno, Italy) twice daily were administered. While the leading follicle reached a diameter of 18 mm, rhCG was used for oocyte triggering. Then, ultrasound-guided oocyte aspiration was conducted 36 hours later.

**Artificial oocyte activation**

Approximately 4 hours after oocyte retrieval, fertilization with ICSI was performed. As previous studies [20, 21], in the AOA group, the calcium ionophore (GM508 CultActive, GYNEMED GmbH & Co. KG, Germany) was incubated at 37 °C in 6% CO2 for 4 hours before application. The injected oocytes were incubated in 50 μl pre-equilibrated calcium ionophore drops individually for 15 min immediately after ICSI. Then, the injected oocytes were removed from the drop and washed twice in HEPES- or MOPS-free medium. After washing, the injected oocytes were transferred to the culture medium for further culture.
Embryo culture and assessment

Embryos were cultured using a microdrop at 37°C in a 6% or 6.5% CO2 incubator. Embryo quality was assessed based on the criteria described by the Istanbul consensus workshop [22]. Embryos were graded on Day 3 after oocyte retrieval as Grade 1 to Grade 3 based on the percentage of fragmentation, the evenness of each blastomere and whether multinucleation was present. In brief, Grade 1 embryos had less than 10% fragmentation, equal-sized blastomeres and no multinucleation; Grade 2 embryos had 10–25% fragmentation, equal-sized blastomeres in the majority of cells and no multinucleation; and Grade 3 embryos had more than 25% fragmentation, blastomeres of unequal size and evidence of multinucleation. Top-quality Day 3 embryos (TQE) were defined as 6–10 cells with grade 1 (<10% fragmentation, equal-sized blastomeres and no multinucleation) in this study. A freeze-all policy was adopted in our reproductive medical center. Because of poor embryo quality in the study population, most of the embryos were cryopreserved in the cleavage stage, and few embryos were extendedly cultured to the blastocyst stage.

Outcome measures

The primary outcomes were cleavage rate and top-quality Day 3 embryo rate. The secondary outcomes included numbers of Day 3 embryos and numbers of top-quality Day 3 embryos.

The cleavage rate was defined as the number of Day 3 embryos divided by the number of fertilized oocytes. The top-quality Day 3 embryo rate was defined as the number of top-quality Day 3 embryos divided by the number of Day 3 embryos.

Statistical analysis

The Kolmogorov–Smirnov test was used to test the normal distribution of continuous variables. A Student’s t test or the Mann–Whitney U test was used to evaluate quantitative variables. A chi-square test was used to assess categorical variables. Logistic regression was used to calculate the odds ratio and 95% confidence intervals (CI) of the two groups (AOA and non-AOA). All data analyses were conducted using the Statistical Package for Social Sciences (SPSS) version 20.0 (Chicago, IL, USA). A two-tailed value of P < 0.05 was considered statistically significant.

Results

As shown in Fig. 1, there were 1090 IVF/ICSI cycles from January 2018 until September 2020. Out of the 1090 cycles, 308 patients met the criteria of POSEIDON Group 4 and received the first IVF-ICSI cycle in our reproductive medical center. Among the 308 patients, there were 29 cases in which the patients were older than 46 years old, 12 cases in which patients were oocytes recipients, and 10 cases in which there were no metaphase II oocytes. Therefore, 49 cycles were excluded. The remaining 259 patients were included and divided into the AOA group (n=91) and the non-AOA group (n=168). Next, 3 patients with total fertilization failure were noted in the AOA group, and 6 patients with total fertilization failure were observed in the non-AOA group. Finally, the AOA group included 88 patients with viable zygotes, and the non-AOA group included 162 patients with viable zygotes for further evaluation of embryo quality.

The baseline characteristics of the study population are summarized in Table 1. No significant differences regarding age, body mass index, infertility duration or AFCs were noted between the two groups. However, more previous IVF attempts, more primary infertility, higher basal FSH levels and lower AMH levels were observed in the AOA group than in the non-AOA group.

As shown in Table 2, there were no significant differences in stimulation duration, gonadotropin dosage, stimulation protocols, number of oocytes retrieved, number of metaphase II oocytes, maturation rate, number of fertilized oocytes, fertilization rate, total fertilization failure rate, number of Day 3 embryos or number of top-quality Day 3 embryos. However, patients in the AOA group had a higher cleavage rate (94.9 ±28.0% vs. 86.5 ±22.8%, P=0.018) and top-quality Day 3 embryo

| Parameters                  | AOA (n=91) | Non-AOA (n=168) | P value |
|-----------------------------|------------|-----------------|---------|
| Age (years)                 | 40.9±2.8   | 40.4±2.7        | 0.138   |
| Body mass index (kg/m²)     | 23.1±3.8   | 23.4±3.5        | 0.540   |
| Infertility duration (years)| 5.0±3.5    | 4.6±3.7         | 0.478   |
| Previous IVF attempts (%)   |            |                 | 0.009   |
| 0                           |            |                 |         |
| 1–2                         | 20.9%(19/91)| 39.3%(66/168)   |         |
| ≥3                          | 42.9%(39/91)| 35.7%(60/168)   |         |
| Types of infertility (%)    |            |                 | 0.033   |
| Primary infertility         | 62.6%(57/91)| 48.8%(82/168)   |         |
| Secondary infertility       | 37.4%(32/91)| 51.2%(86/168)   |         |
| Basal FSH (IU/l)            | 8.5±9.3    | 5.4±3.8         | 0.003   |
| Antral follicle counts (n)  | 6.3±3.0    | 6.9±3.6         | 0.156   |
| Anti-Müllerian hormone (ng/ mL) | 0.57±0.32 | 0.67±0.32 | 0.028 |

Data are presented as the mean ± standard deviation and %

AOA Artificial oocyte activation, IVF In vitro fertilization, FSH Follicle-stimulating hormone
The TQE (Top-qualitY Day 3 embryos) rate (53.2 ± 39.1% vs. 37.2 ± 42.7%, P = 0.004) was higher in the AOA group than in the non-AOA group. Moreover, the percentage of more than 1 TQE (73.9% vs. 55.6%, P = 0.005) and TQE rate ≥ 50 (60.2% vs. 42.5%, P = 0.008) were higher in the AOA group than in the non-AOA group.

In Table 3, a binary logistic regression analysis was performed to analyze whether using AOA would affect TQE. Confounding parameters such as age, body mass index, previous IVF attempts, types of infertility, basal FSH, AFCs, AMH and number of metaphase II oocytes were included in the analysis. The multivariate analysis revealed that AOA positively correlated with more than 1 TQE (adjusted OR 3.24, 95% CI 1.63–6.45, P = 0.001) and TQE rate ≥ 50 (adjusted OR 2.14, 95% CI 1.20–3.80, P = 0.010). The number of metaphase II oocytes was also positively related to more than 1 TQE (adjusted OR 2.19, 95% CI 1.65–2.91, P < 0.001) and TQE rate ≥ 50 (adjusted OR 1.20, 95% CI 1.03–1.41, P = 0.024).

### Table 2: Cycle characteristics of POSEIDON Group 4 patients with AOA or non-AOA

| Parameters                        | AOA (n = 91)     | Non-AOA (n = 168) | P value |
|-----------------------------------|------------------|--------------------|---------|
| Stimulation duration (days)       | 11.1 ± 2.2       | 11.0 ± 2.1         | 0.684   |
| Gonadotropin dosage (IU)          | 3132.4 ± 701.0   | 3132.4 ± 697.9     | 1.000   |
| Stimulation protocols (%)         |                  |                    | 0.807   |
| GnRH antagonist protocol (%)      | 60.4% (55/91)    | 64.3% (108/168)    |         |
| PPOS protocol (%)                 | 27.5% (25/91)    | 25.6% (43/168)     |         |
| Ultralong protocol (%)            | 12.1% (11/91)    | 10.1% (17/168)     |         |
| No. of oocytes retrieved (n)      | 41 ± 2.6         | 45 ± 3.0           | 0.329   |
| No. of metaphase II oocytes (n)   | 32 ± 2.1         | 36 ± 2.5           | 0.132   |
| Maturation rate (%)               | 80.7 ± 20.8      | 82.1 ± 19.3        | 0.581   |
| No. of fertilized oocytes (n)     | 2.7 ± 1.8        | 3.0 ± 2.1          | 0.258   |
| Fertilization rate (%)            | 86.2 ± 24.1      | 83.0 ± 26.0        | 0.340   |
| Total fertilization failure rate (%) | 3.3%             | 4.2%               | 0.715   |
| No. of Day 3 embryos (n)          | 2.6 ± 1.6        | 2.8 ± 2.1          | 0.443   |
| Cleavage rate (%)                 | 94.9 ± 28.0      | 86.5 ± 22.8        | 0.018   |
| No. of top-quality Day 3 embryos (n) | 1.4 ± 1.3       | 1.2 ± 1.5          | 0.414   |
| Top-quality Day 3 embryos rate (%) | 73.9%            | 55.6%              | 0.005   |
| Top-quality Day 3 embryos rate ≥ 50 | 53.2 ± 39.1     | 37.2 ± 42.7        | 0.004   |

Data are presented as the mean ± standard deviation and %

AOA Artificial oocyte activation, GnRH Gonadotropin releasing Hormone, PPOS Progestin priming ovulation stimulation.

### Table 3: Analyses of factors affecting top-quality Day 3 embryos (TQE) in POSEIDON Group 4 patients using logistic regression

| ≤1 TQE | Adjusted OR (95% CI) | P value | TQE rate ≥ 50 | Adjusted OR (95% CI) | P value |
|--------|----------------------|---------|---------------|----------------------|---------|
| AOA vs. non-AOA | 3.24 (1.63–6.45) | 0.001 | 2.14 (1.20–3.80) | 0.010 |
| Age (years) | 1.05 (0.94–1.18) | 0.386 | 1.02 (0.93–1.13) | 0.658 |
| BMI (kg/m²) | 1.01 (0.92–1.10) | 0.845 | 0.97 (0.90–1.05) | 0.496 |
| Previous IVF attempts | 0.83 (0.55–1.25) | 0.361 | 0.80 (0.56–1.12) | 0.193 |
| Types of infertility | 0.70 (0.36–1.33) | 0.269 | 0.85 (0.49–1.47) | 0.552 |
| Basal FSH (IU/l) | 1.03 (0.97–1.09) | 0.378 | 1.03 (0.97–1.08) | 0.364 |
| AFC (n) | 1.00 (0.88–1.13) | 0.943 | 0.99 (0.89–1.11) | 0.891 |
| AMH (ng/mL) | 0.47 (0.16–1.41) | 0.179 | 0.82 (0.32–2.07) | 0.670 |
| No. of MII oocytes (n) | 2.19 (1.65–2.91) | < 0.001 | 1.20 (1.03–1.41) | 0.024 |

OR Odds ratio, CI Confidence interval, AOA Artificial oocyte activation, BMI Body mass index, IVF in vitro fertilization, FSH Follicle-stimulating hormone, AFC Antral follicle count, AMH Anti-Müllerian hormone, MII Metaphase II.
We then divided our study population into 2 subgroups based on the age of 40 years old (Table 4). In the subgroup of age ≥40 years old, compared to the non-AOA group, the AOA group obtained a significantly higher cleavage rate (96.3 ± 31.3% vs. 86.6 ± 24.3%, \( P = 0.035 \)) and TQE rate (56.8 ± 37.7% vs. 34.6 ± 37.7%, \( P = 0.001 \)) as well as a higher percentage of more than 1 TQE (64.9% vs. 41.1%, \( P = 0.004 \)). However, in the subgroup of age < 40 years old, cleavage rate, TQE rate, percentage of more than 1 TQE and percentage of TQE ≥50 were similar between the two groups.

As presented in Table 5, a binary logistic regression analysis was conducted to analyze the effects of AOA on TQE in the subgroup of age ≥40 years old. Age, body mass index, previous IVF attempts, types of infertility, basal FSH, AFCs, AMH and number of metaphase II oocytes were considered confounding factors in this analysis. The multivariate analysis revealed that AOA positively correlated with more than 1 TQE (adjusted

| Parameters                                      | < 40 (35–39) y/o | ≥40 (40–45) y/o | \( P \) value | < 40 (35–39) y/o | ≥40 (40–45) y/o | \( P \) value |
|------------------------------------------------|-----------------|----------------|-------------|-----------------|----------------|-------------|
| Age (years)                                    | 37.8 ± 1.5      | 37.5 ± 1.3     | 0.378       | 42.6 ± 1.6      | 42.3 ± 1.4     | 0.240       |
| Body mass index (kg/m²)                        | 22.4 ± 3.0      | 23.1 ± 3.0     | 0.263       | 23.5 ± 4.2      | 23.5 ± 3.7     | 0.889       |
| Antral follicle counts (n)                     | 5.9 ± 2.6       | 7.8 ± 3.6      | 0.012       | 6.5 ± 3.2       | 6.3 ± 3.5      | 0.794       |
| Anti-Müllerian hormone (ng/ml)                 | 0.50 ± 0.30     | 0.72 ± 0.29    | 0.001       | 0.61 ± 0.33     | 0.63 ± 0.34    | 0.728       |
| No. of oocytes retrieved (n)                   | 3.3 ± 2.1       | 5.0 ± 3.1      | 0.008       | 4.5 ± 2.8       | 4.1 ± 2.9      | 0.394       |
| No. of metaphase II oocytes (n)                | 2.6 ± 1.8       | 4.0 ± 2.5      | 0.007       | 3.5 ± 2.2       | 3.4 ± 2.4      | 0.833       |
| Maturation rate (%)                            | 81.3 ± 21.8     | 82.3 ± 17.6    | 0.808       | 80.4 ± 20.4     | 82.0 ± 20.5    | 0.626       |
| No. of fertilized oocytes (n)                  | 2.3 ± 1.7       | 3.4 ± 2.3      | 0.024       | 3.0 ± 1.9       | 2.8 ± 2.0      | 0.618       |
| Fertilization rate (%)                         | 86.9 ± 23.5     | 82.5 ± 24.8    | 0.403       | 85.8 ± 24.6     | 83.4 ± 26.8    | 0.575       |
| No. of Day 3 embryos (n)                       | 2.2 ± 1.5       | 3.0 ± 2.3      | 0.084       | 2.8 ± 1.6       | 2.6 ± 2.0      | 0.547       |
| Cleavage rate (%)                              | 92.2 ± 20.8     | 86.3 ± 20.6    | 0.200       | 96.3 ± 31.3     | 86.6 ± 24.3    | 0.035       |
| No. of top-quality Day 3 embryos (n)           | 1.2 ± 1.4       | 1.3 ± 1.6      | 0.604       | 1.5 ± 1.2       | 1.2 ± 1.4      | 0.120       |
| ≥1 top-quality Day 3 embryos                   | 64.5%           | 58.5%          | 0.571       | 78.9%           | 53.7%          | 0.002       |
| Top-quality Day 3 embryos rate (%)             | 46.5 ± 41.5     | 37.1 ± 37.0    | 0.267       | 56.8 ± 37.7     | 34.6 ± 37.7    | 0.001       |
| Top-quality Day 3 embryos rate ≥50             | 51.6%           | 44.6%          | 0.521       | 64.9%           | 41.1%          | 0.004       |

Data are presented as the mean ± standard deviation and % (n)

AOA Artificial oocyte activation

Table 4 Subgroup analyses (categorized relative to the age of 40 years) of POSEIDIN Group 4 patients with AOA or non-AOA

Table 5 Analyses of factors affecting top-quality Day 3 embryos (TQE) in POSEIDON Group 4 patients aged ≥40 years using logistic regression

| ≥1 TQE                              | Adjusted OR (95% CI) | \( P \) value | TQE rate ≥50          | Adjusted OR (95% CI) | \( P \) value |
|-------------------------------------|----------------------|-------------|-----------------------|----------------------|-------------|
| AOA vs. non-AOA                     | 3.83 (1.58–9.29)     | 0.003       | 2.79 (1.34–5.82)      | 0.006                |
| Age (years)                         | 0.99 (0.75–1.30)     | 0.923       | 0.92 (0.73–1.17)      | 0.493                |
| BMI (kg/m²)                         | 0.96 (0.87–1.07)     | 0.475       | 0.94 (0.86–1.03)      | 0.153                |
| Previous IVF attempts               | 0.77 (0.45–1.34)     | 0.361       | 0.79 (0.50–1.24)      | 0.303                |
| Types of infertility               | 0.76 (0.33–1.76)     | 0.524       | 0.92 (0.45–1.88)      | 0.818                |
| Basal FSH (IU/l)                    | 1.04 (0.95–1.15)     | 0.391       | 1.04 (0.96–1.12)      | 0.394                |
| AFC (n)                             | 1.01 (0.86–1.20)     | 0.873       | 0.98 (0.86–1.13)      | 0.811                |
| AMH (ng/mL)                         | 0.32 (0.08–1.23)     | 0.098       | 0.56 (0.18–1.78)      | 0.329                |
| No. of MII oocytes (n)              | 2.02 (1.42–2.89)     | < 0.001     | 1.18 (0.96–1.44)      | 0.119                |

OR Odds ratio, CI Confidence interval, AOA Artificial oocyte activation, BMI Body mass index, IVF in vitro fertilization, FSH Follicle-stimulating hormone, AFC Antral follicle count, AMH Anti-Müllerian hormone, MII Metaphase II
Discussion
This was a retrospective study focusing on the effects of AOA on the quality of embryos in patients who fulfilled the POSIDON Group 4 criteria and underwent IVF-ICSI cycles. This study showed that AOA with calcium ionophores were associated with a higher cleavage rate and TQE rate. In addition, the multivariate analysis revealed a 3.24-fold increase in the possibility of more than 1 TQE (95% CI 1.63–6.45, P = 0.001) and a 2.14-fold increase in the possibility of a TQE rate ≥ 50 (95% CI 1.20–3.80, P = 0.001) in the POSIDON Group 4 patients with AOA compared to those without AOA.

AOA with calcium ionophores can activate oocytes by increasing the permeability of calcium in the cell membrane and inducing the entry of extracellular calcium into the cell, leading to calcium oscillations [23]. Normal calcium oscillations induced by the specific sperm protein phospholipase C zeta (PLCζ) may also play a role in the development of embryos [24–26]. Calcium oscillations stimulate the processes that are required in embryonic development, such as mitotic cleavage, in numerous species of invertebrates and vertebrates [27]. Calcium signals mediate the cell cycle of early embryogenesis. Embryos undergo a series of rapid cell divisions after fertilization [28]. The different frequencies and patterns of calcium oscillations in specific species could affect the induction of oocyte activation and embryo development [29]. The frequency of calcium oscillations was related to different morphogenesis of early embryonic stages. A certain range of the frequency of calcium oscillations is optimal for embryogenesis. Calcium oscillations that are too frequent and too rare are harmful to the embryos [30]. Meiosis and embryonic divisions are regulated by the pattern of calcium oscillations, and a certain threshold of calcium oscillations is essential to induce the formation of pronuclei [31, 32]. The concentration of PLCζ is positively related to the frequency of calcium oscillations. A higher concentration of PLCζ results in a higher frequency of calcium oscillations, which will cause cleavage stage arrest, while a appropriate concentration of PLCζ leads to a appropriate frequency of calcium oscillations, which will activate embryonic development to the blastocyst stage [33, 34]. The calcium-binding proteins in the human endoplasmic reticulum and intracellular calcium channels that regulate inositol 1,4,5-trisphosphate receptors (IP3Rs) play an important role in the regulation of calcium signaling during oocyte maturation, fertilization and early embryo development as calcium signaling is a key factor in early embryonic cleavage [35, 36]. Taken together, calcium oscillations may be an essential element of early embryonic division [37]. Therefore, AOA with calcium ionophores, which could enhance calcium oscillations, may have beneficial effects on embryo development.

The abovementioned studies support our results that AOA with calcium ionophores are positively associated with high embryo quality. In a randomized, open-label trial proposed by Mohamed Fawzy et al., 343 participants, 18–40 years of age, were divided into 3 groups: AOA with SrCl2 following ICSI (n = 115), AOA with calcimycin after ICSI (n = 113) and AOA with ICSI alone (n = 115). AOA with SrCl2 following ICSI led to better embryological outcomes, such as top-quality Day 3 embryos (OR 5.16, 95% CI 4.11–6.48, P < 0.0001), blastocyst formation rate (OR 1.93, 95% CI 1.60–2.34, P < 0.0001), and high-quality blastocysts (OR 1.85, 95% CI 1.51–2.26, P < 0.0001), compared to ICSI alone. Moreover, a higher blastocyst formation rate (OR 1.25, 95% CI 1.03–1.52, P = 0.026) was observed in the AOA with calcimycin group after ICSI than in the AOA with ICSI alone group [12]. A meta-analysis conducted by Murugesu and colleagues demonstrated that AOA with calcium ionophores following ICSI significantly improved fertilization, cleavage, blastulation, pregnancy rates and live birth rates. In terms of embryo quality, a better cleavage rate (OR 2.28, 95% CI 1.23–4.21, P = 0.06) and blastocyst formation rate (OR 6.7, 95% CI 2.59–17.28, P = 0.003) were found in the AOA with calcium ionophore group than in the non-AOA group [38]. A prospective study that investigated the use of AOA with calcium ionophores in patients with PLCζ deficiency showed no significant difference between the control (n = 113 oocytes) without AOA (n = 106 oocytes) and AOA groups (n = 114 oocytes) in terms of cleavage rate (91.7 ± 2.8%, 90.9 ± 4.6%, and 95.2 ± 3.4%) and embryo quality score (2.5 ± 0.1, 2.3 ± 0.2, and 2.4 ± 0.2). However, all the female patients enrolled in this study were under the age of 35 years old [39]. In an updated systemic review and meta-analysis, AOA with calcium ionophore treatment significantly improved the blastocyst formation rate (OR 3.59, 95% CI, 1.34–9.60, P = 0.01) but did not improve the cleavage rate (OR 1.68, 95% CI, 0.90–3.13, P = 0.10) or top-quality embryo rate (OR 1.15, 95% CI, 0.72–1.82, P = 0.55) [40]. Thus, more large-scale studies are needed to confirm whether AOA with calcium ionophores can improve embryo quality.

To examine the effects of AOA with calcium ionophores on embryo quality in older patients, the study population was divided into 2 subgroups based on the age of 40 years old. The results showed that AOA with
calcium ionophores were associated with a higher cleavage rate and TQE rate only in the subgroup aged ≥40 years old and not in the subgroup aged <40 years old. In addition, the multivariate analysis revealed that the subgroup of age ≥40 years old with AOA had a 3.83-fold increase in the possibility of more than 1 TQE (95% CI 1.58–9.29, \( P = 0.003 \)) and a 2.79-fold increase in the possibility of TQE rate ≥50 (95% CI 1.34–5.82, \( P = 0.006 \)) compared to the subgroup of age ≥40 years old without AOA. Impaired oocyte maturation, fertilization and embryo development were observed in advanced maternal age [41]. Increased reactive oxygen species (ROS) in aged oocytes change the regulation of the intracellular calcium signal and affect calcium oscillations in fertilized oocytes, which may be associated with poor embryo development [42, 43]. Therefore, AOA with calcium ionophores may have more beneficial effects on older women as these women are more likely to suffer from low intracellular calcium stores and abnormal calcium oscillations. This hypothesis is supported by our result that a higher cleavage rate and TQE rate were only found in the subgroup aged ≥40 years old with AOA rather than in the subgroup aged <40 years old with AOA. However, more large-scale studies are required to verify our results.

There are some limitations in our study. First, the retrospective design and limited study population are major limitations of this study. Large-scale randomized controlled trials are needed to verify our results. Next, a power calculation is lacking in this study because all patients who met the POSEIDON Group 4 criteria during study period were included. Moreover, the basal characteristics were not similar regarding previous IVF attempts, types of infertility, basal FSH and AMH between the AOA and non-AOA groups. Besides, different IVF protocols, including the antagonist protocol, ultralong protocol, and PPOS protocol, were used in this study, which may be another source of bias. Finally, we should interpret the data cautiously in the subgroup analyses because of the potential bias from the small population. A strength of this study is that all IVF cycles were performed by the same physician and embryologist.

In conclusion, our data suggest that AOA with calcium ionophores may improve embryo quality in POSEIDON Group 4 patients undergoing IVF-ICSI cycles, especially in those older than 40 years old.

Acknowledgments
This work was generously supported by grants KSVGH21-CT1-27 from Kaohsiung Veterans General Hospital.

Authors’ contributions
KHT, PHL and LTL contributed to the conception and design of the study; PFL, SGV and WPS organized the database; GJL, SGV, MM and HWT performed the statistical analysis; TET wrote the first draft of the manuscript; LTL wrote sections of the manuscript. All authors contributed to manuscript revision and read and approved the submitted version.

Funding
Not applicable.

Availability of data and materials
The datasets used and analyzed in this article are available from the corresponding author on reasonable request.

Competing interests
The authors declare that they do not have any competing interests.

Supporting information
Additional file 1. Power calculation
Additional file 2. Multivariate analysis
Additional file 3. Baseline characteristics

References
1. Palermo G, Joris H, Devroey P, Van Steirteghem AC. Pregnancy after intracytoplasmic injection of single spermatozoon into an oocyte. Lancet. 1992;340(8810):17–8.
2. Kashir J, Heindryckx B, Jones C, De Sutter P, Parrington J, Coward K. Oocyte activation, phospholipase C zeta and human infertility. Hum Reprod Update. 2010;16(6):690–703.
3. Vanden Meerschaut F, Nikiforaki D, Heindryckx B, De Sutter P. Assisted oocyte activation following ICSI fertilization failure. Reprod Biomed Online. 2014;28(5):560–71.
4. Tesarik J, Sousa M, Testart J. Human oocyte activation after intracytoplasmic sperm injection. Hum Reprod. 1999;14(3):511–8.
5. Swain JE, Pool TB. ART failure: oocyte contributions to unsuccessful fertilization. Hum Reprod Update. 2008;14(5):431–46.
6. Sfondouris IA, Nastri CO, Lima ML, Tahmasbipourmarzouni E, Raine-Fenning N, Martins WP. Artificial oocyte activation to improve reproductive
outcomes in women with previous fertilization failure: a systematic review and meta-analysis of RCTs. Hum Reprod. 2015;30(8):1831–41.

7. Alberio R, Zakhartchenko V, Motlik J, Wolf E. Mammalian oocyte activation: lessons from the sperm and implications for nuclear transfer. Int J Dev Biol. 2001;45(7):797–809.

8. Nasr-Elfahami MH, Deemeh MR, Tavalaee M. Artificial oocyte activation and intrauterine sperm injection. Fertil Steril. 2010;94(2):S20–6.

9. Heindryckx B, De Van der Elst J, De Sutter P, Dhont M. Treatment option for sperm- or oocyte-related fertilization failure: assisted oocyte activation following diagnostic heterologous ICSI. Hum Reprod. 2005;20(8):2237–41.

10. Heindryckx B, De Gheselle S, Gennis J, Dhont M, De Sutter P. Efficiency of assisted oocyte activation as a solution for failed intrauterine sperm injection. Reprod Biomed Online. 2008;17(5):662–8.

11. Bonte D, Ferrer-Buitrago M, Dhaenens L, Popovic M, Thys V, De Croo I, et al. Assisted oocyte activation significantly increases fertilization and pregnancy outcome in patients with low and total failed fertilization after intrauterine sperm injection: a 17-year retrospective study. Fertil Steril. 2019;112(2):266–74.

12. Fawzy M, Emad M, Mahran A, Sabry M, Fetih AN, Abdelghafar H, et al. Artificial oocyte activation with SrCl2 or calcimycin after ICSI improves clinical and embryological outcomes compared with ICSI alone: results of a randomized clinical trial. Hum Reprod. 2018;33(9):1636–44.

13. Li M, Zhang D, He X, Chen B, Li Q, Ding D, et al. Artificial oocyte activation to improve reproductive outcomes in couples with various causes of infertility: a retrospective cohort study. Reprod Biomed Online. 2020;40(4):501–9.

14. Esteves SC, Roque M, Bedoschi GM, Conforti A, Humaidan P, Alviggi C. Defining Low Prognosis Patients Undergoing Assisted Reproductive Technology: POSEIDON Criteria-The Why. Front Endocrinol (Lausanne). 2019;10:661.

15. Alviggi C, Andersen CY, Buehler K, Conforti A, De Placido G, Esteves SC, et al. A new more detailed stratification of low responders to ovarioc stimulation: from a poor ovarian response to a low prognosis concept. Fertil Steril. 2016;105(5):1452–3.

16. Esteves SC, Alviggi C, Humaidan P, Fischer R, Andersen CY, Conforti A, et al. The POSEIDON Criteria and its Measure of Success Through the Eyes of Clinicians and Embryologists. Front Endocrinol (Lausanne). 2019;10:814.

17. Humaidan P, Alviggi C, Fischer R, Esteves SC. The novel POSEIDON stratification of ‘Low prognosis patients in Assisted Reproductive Technology’ and its proposed marker of successful outcome. F1000Res. 2016;5:1201.

18. Conforti A, Esteves SC, Picarelle S, Iorio G, Rancia E, Zullo F, et al. Novel approaches for diagnosis and management of low prognosis patients in assisted reproductive technology: the POSEIDON concept. Panminerva Med. 2019;61(1):24–9.

19. Haahr T, Dosouto C, Alviggi C, Esteves SC, Humaidan P. Management Strategies for POSEIDON Groups 3 and 4. Front Endocrinol (Lausanne). 2019;10:614.

20. Ebner T, Montag M, Montag M, Van der Ven K, Van der Ven H, Ebner T, et al. Live birth after artificial oocyte activation using a ready-to-use ionophore: a prospective multicentre study. Reprod Biomed Online. 2015;30(4):359–65.

21. Caglar Aytac P, Kilicdag EB, Haydardedeoglu B, Simsek E, Cok T, Parlak‑Seyrek M, et al. Live birth after artificial oocyte activation using a ready‑to‑use ionophore: a prospective multicentre study. Reprod Biomed Online. 2019;12(6):1186–749.

22. Alpha Scientists in Reproductive Medicine and ESHRE Special Interest Group of Embryology. The Istanbul consensus workshop on embryo assessment: proceedings of an expert meeting. Hum Reprod. 2011;26(6):1270–83.

23. Anifandis G, Michopoulos A, Daponte A, Chatzemeletiou K, Simopoulou M, Messini C, et al. Artificial oocyte activation: physiological, pathophysiological and ethical aspects. Syst Biol Reprod Med. 2019;65(1):13–11.

24. Machaty Z, Wang C, Lee K, Zhang L. Fertility: Store-Operated Ca (2+) Entry in Germ Cells: Role in Egg Activation. Adv Exp Med Biol. 2017;993:577–93.

25. Harder A, Godwin J, Ruas M, Lee HC, Ferrer-Buitrago M, Ardestani G, et al. PLCC3 is the physiological trigger of the Ca (2+) oscillations that induce embryogenesis in mammals but conception can occur in its absence. Development. 2017;144(16):2914–24.

26. Saleh A, Kashir J, Thanassoula S, Safieh-Garabedian B, Lai FA, Nomikos M. Essential Role of Sperm-Specific PLC-Zeta in Egg Activation and Male Factor Infertility: An Update. Front Cell Dev Biol. 2020;8:28.

27. Whitaker M. Calcium microdomains and cell cycle control. Cell Calcium. 2006;40(5):585–92.

28. Whitaker M. Calcium at fertilization and in early development. Physiol Rev. 2006;86(1):25–88.

29. Cooney MA, Malcuit C, Cheon B, Holland MK, Fissore RA, D’Cruz NT. Species-specific differences in the activity and nuclear localization of murine and bovine phospholipase C: zeta 1. Biol Reprod. 2010;83(1):92–101.

30. Milewski R, Szpila M, Ajduk A. Dynamics of cytoplasm and cleavage divisions correlates with preimplantation embryo development. Reprod. 2018;155(1):1–14.

31. Ducibella T, Huneau D, Angelichio E, Xu Z, Schultz RM, Kopf GS, et al. Egg-to-embryo transition is driven by differential responses to Ca (2+) oscillation number. Dev Biol. 2002;250(2):280–91.

32. Ozil JP, Markoulaki S, Toth S, Matson S, Banitez B, Knott JG, et al. Egg activation events are regulated by the duration of a sustained [Ca2+]cyt signal in the mouse. Dev Biol. 2005;282(1):39–54.

33. Cox LJ, Larman MG, Saunders CM, Hashimoto K, Swann K, Lai FA. Sperm phospholipase Czeta from humans and cynomolgus monkeys triggers Ca2+ oscillations, activation and development of mouse oocytes. Reproduction. 2002;124(5):611–23.

34. Rogers NT, Hobson E, Pickering S, Lai FA, Braude P, Swann K. Phospholipase Czeta causes Ca2+ oscillations and parthenogenetic activation of human oocytes. Reproduction. 2004;128(6):697–702.

35. Balaker H, Dzika E, Sojecki A, Librach C, Michalak M, Opas M. Calcium-binding proteins and calcium-release channels in human maturing oocytes, pronuclear zygotes and early preimplantation embryos. Hum Reprod. 2002;17(11):2938–47.

36. Goud PT, Goud AP, Van Oostveldt P, Dhont M. Presence and dynamic redistribution of type 1 insitol 1,4,5-trisphosphate receptors in human oocytes and embryos during in-vitro maturation, fertilization and early cleavage divisions. Mol Hum Reprod. 1999;5(5):441–51.

37. Swanson CA, Arkin AP, Ross J. An endogenous calcium oscillator may control early embryonic division. Proc Natl Acad Sci U S A. 1997;94(4):1194–9.

38. Murugesu S, Sasso S, Jones BP, Braceywel-Milnes T, Athanasou T, Mania A, et al. Does the use of calcium ionophore during artificial oocyte activation demonstrate an effect on pregnancy rate? A meta-analysis. Fertil Steril. 2017;108(3):468–482 e463.

39. Nazarian H, Azad N, Nazari L, Pinyaei A, Heidari MH, Masteri-Farahani R, et al. Effect of Artificial Oocyte Activation on Intra-Cytoplasmic Sperm Injection Outcomes in Patients with Lower Percentage of Sperm Containing Phospholipase CC, A Randomized Clinical Trial. J Reprod Infertil. 2019;20(1):3–9.

40. Shan Y, Zhao H, Zhao D, Wang J, Cui Y, Bao H. Assisted Oocyte Activation With Calcium Ionophore Improves Pregnancy Outcomes and Offspring Safety in Infertile Patients: A Systematic Review and Meta-Analysis. Front Physiol. 2021;12:751905.

41. Rehman RM, Mahmood H, Syed F, Syed H, Gul H. Intracytoplasmic sperm injection and advanced maternal age: Success or treatment failure? Pak J Pharm Sci. 2019;32(4):1495–9.

42. Takahashi T, Takahashi E, Igarashi H, Tezuka N, Kurachi H. Impact of oxidative stress in aged mouse oocytes on calcium oscillations at fertilization. Mol Reprod Dev. 2005;66(2):143–52.

43. Takahashi T, Igarashi H, Kawagoe J, Aita M, Hara S, Kurachi H. Poor embryo development in mouse oocytes aged in vitro is associated with impaired calcium homeostasis. Biol Reprod. 2009;80(3):493–502.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.